

# Joseph F Merola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/724640/publications.pdf>

Version: 2024-02-01

212  
papers

5,622  
citations

109264

35  
h-index

106281

65  
g-index

218  
all docs

218  
docs citations

218  
times ranked

4946  
citing authors

#	ARTICLE	IF	CITATIONS
1	Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 86-93.	0.6	16
2	Coronary microvascular dysfunction in patients with psoriasis. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 37-42.	1.4	18
3	Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1670-1675.	1.1	7
4	Hepatitis B and C among patients with hidradenitis suppurativa: a population-based study. <i>International Journal of Dermatology</i> , 2022, 61, 84-88.	0.5	3
5	Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1075-1080.	0.6	4
6	A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1907-1915.	1.1	6
7	Tofacitinib for refractory chilblain lupus erythematosus. <i>International Journal of Dermatology</i> , 2022, 61, .	0.5	7
8	Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 423-425.	0.6	15
9	Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 748-757.	0.6	20
10	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2022, 238, 430-437.	0.9	4
11	Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvistas™ Psoriasis Registry. <i>Dermatology and Therapy</i> , 2022, 12, 97-119.	1.4	3
12	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2026-2029.e4.	0.3	0
13	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 80-86.	0.5	29
14	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	1.4	30
15	Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	8
16	A novel variant in the GNAS complex locus causes Albright hereditary osteodystrophy with pseudopseudohypoparathyroidism. <i>JAAD Case Reports</i> , 2022, 21, 103-105.	0.4	0
17	Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists. <i>Clinical Rheumatology</i> , 2022, 41, 1271-1283.	1.0	6
18	Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 399-400.	0.6	9

#	ARTICLE	IF	CITATIONS
19	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. <i>Dermatology and Therapy</i> , 2022, 12, 787-800.	1.4	6
20	Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 797-806.	1.3	36
21	Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures. <i>Scandinavian Journal of Rheumatology</i> , 2022, , 1-9.	0.6	6
22	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. <i>RMD Open</i> , 2022, 8, e002195.	1.8	11
23	Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. <i>Rheumatology and Therapy</i> , 2022, 9, 935-955.	1.1	10
24	Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis. <i>Dermatology and Therapy</i> , 2022, 12, 753-760.	1.4	1
25	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. <i>Dermatology and Therapy</i> , 2022, 12, 911.	1.4	4
26	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. <i>Journal of Rheumatology</i> , 2022, , jrheum.211328.	1.0	0
27	Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. <i>Journal of Dermatological Treatment</i> , 2022, , 1-28.	1.1	1
28	Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
29	Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement. <i>Dermatologic Therapy</i> , 2022, 35, e15518.	0.8	1
30	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. <i>Journal of Rheumatology</i> , 2022, 49, 885-893.	1.0	12
31	Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. <i>Journal of Rheumatology</i> , 2022, 49, 894-902.	1.0	7
32	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. <i>Journal of Rheumatology</i> , 2022, , .	1.0	0
33	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 735.	2.0	22
34	Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 692-703.	1.4	19
35	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: <sc>Three-Year</sc> Results From a Phase <sc>Ib</sc> Randomized Controlled Trial and Its <sc>Open-Label</sc> Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1959-1970.	2.9	16
36	Measuring fatigue: a meta-review. <i>International Journal of Dermatology</i> , 2021, 60, 1053-1069.	0.5	26

#	ARTICLE	IF	CITATIONS
37	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021, 237, 151-157.	0.9	6
38	Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 495-497.	0.6	6
39	De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 864-869.	0.6	15
40	Axial psoriatic arthritis: An update for dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 92-101.	0.6	41
41	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 300-311.	0.6	20
42	Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 249-252.	0.6	2
43	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	0.9	13
44	Pseudovasculitis: an etiology not to miss. <i>Clinical Rheumatology</i> , 2021, 40, 2505-2506.	1.0	0
45	Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. <i>RMD Open</i> , 2021, 7, e001484.	1.8	1
46	Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021, 11, 253-263.	1.4	3
47	Severe recalcitrant otic lichen planus treated with mycophenolate mofetil. <i>JAAD Case Reports</i> , 2021, 8, 1-3.	0.4	4
48	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021, 17, 238-243.	3.5	23
49	RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin. <i>Lupus Science and Medicine</i> , 2021, 8, e000428.	1.1	6
50	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201671.	1.0	6
51	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 431-431.	0.7	15
52	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2212-2220.	2.3	24
53	Pustular Psoriasis and Associated Musculoskeletal Disorders. <i>Journal of Rheumatology</i> , 2021, , jrheum.201673.	1.0	3
54	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 1227-1239.	13.9	143
56	Lack of association between tumor necrosis factor- $\alpha$ inhibitor use and exacerbation of lupus erythematosus: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	1
57	P189â€fComparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study. <i>Rheumatology</i> , 2021, 60, .	0.9	0
58	Step Therapy Re-Imagined. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 88-89.	0.3	1
59	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021, 157, 805.	2.0	21
60	Seroconversion of severe acute respiratory syndrome coronavirus 2â€“infected patients on immunosuppression: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1409-1412.	0.6	4
61	Hidradenitis suppurativa and sleep disorders: a populationâ€based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e520-e522.	1.3	6
62	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2â€“Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	0.6	88
63	Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis. <i>Dermatology and Therapy</i> , 2021, 11, 1199-1216.	1.4	5
64	Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2021, 157, 880-882.	2.0	6
65	Non-Medical Switching Impact on Patients and Providers â€“ Psoriatic Disease Community Taking a Stand. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 126-127.	0.3	0
66	Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients. <i>JAAD International</i> , 2021, 3, 111-114.	1.1	3
67	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BEâVIVID and BEâREADY Phaseâ3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1551-1569.	1.4	4
68	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderateâ€toâ€severe plaque psoriasis: results from EXCEED, a randomized, doubleâ€blind headâ€toâ€head monotherapy study. <i>British Journal of Dermatology</i> , 2021, 185, 1124-1134.	1.4	21
69	Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 71-78.	0.6	23
70	The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 517-519.	0.6	1
71	Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1106-1117.	0.5	1
72	Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4081.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey. <i>British Journal of Dermatology</i> , 2021, 185, 1264-1265.	1.4	4
74	Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. <i>Current Atherosclerosis Reports</i> , 2021, 23, 67.	2.0	23
75	Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. <i>JAAD Case Reports</i> , 2021, 17, 126-129.	0.4	11
76	A case of paradoxical fibrosis and development of morphea in a patient on dupilumab. <i>JAAD Case Reports</i> , 2021, 17, 7-8.	0.4	6
77	Does psoriasis treatment affect PsA development?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 708-709.	3.5	8
78	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab076.	0.3	4
79	Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective. <i>Dermatology and Therapy</i> , 2021, 11, 2123-2131.	1.4	0
80	Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. <i>Lupus Science and Medicine</i> , 2021, 8, e000529.	1.1	9
81	Psoriatic arthritis for dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, 31, 662-679.	1.1	52
82	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , 2020, 182, 410-417.	1.4	25
83	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 54-61.	0.6	4
84	Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 109-117.	3.3	6
85	Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study. <i>Journal of Rheumatology</i> , 2020, 47, 548-552.	1.0	24
86	P279 Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head comparison study ECLIPSE over 1 year. <i>Rheumatology</i> , 2020, 59, .	0.9	0
87	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020, 20, S80-S83.	0.8	1
88	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , 2020, 7, 617-637.	1.1	17
89	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020, 22, 78.	2.1	10
90	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43

#	ARTICLE	IF	CITATIONS
91	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1367-1374.	0.6	48
92	&lt;p&gt;Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 949-961.	0.8	10
93	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2020, 156, 901.	2.0	18
94	Older adults on systemic treatment for psoriasis and risk of infection: a propensity score-matched population-based study. <i>British Journal of Dermatology</i> , 2020, 183, 564-566.	1.4	5
95	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1337-1345.	0.6	9
96	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1150-1159.	0.6	27
97	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	6.3	122
98	The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2051-2058.	1.3	5
99	Indoor tanning use is associated with psoriasis in the Nurses' Health Study II. <i>British Journal of Dermatology</i> , 2020, 183, 384-386.	1.4	0
100	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 267-283.	1.3	2
101	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 323-338.	3.3	6
102	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020, 156, 342.	2.0	16
103	Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1257-1262.	1.3	14
104	Mycophenolate Mofetil for Eosinophilic Fasciitis. <i>JAMA Dermatology</i> , 2020, 156, 595.	2.0	6
105	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. <i>Dermatology and Therapy</i> , 2020, 10, 351-364.	1.4	18
106	Comorbidities associated with psoriatic arthritis: Review and update. <i>Clinical Immunology</i> , 2020, 214, 108397.	1.4	83
107	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2809-2820.	1.3	13
108	Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. <i>Journal of Dermatological Treatment</i> , 2019, 30, 141-149.	1.1	23

#	ARTICLE	IF	CITATIONS
109	Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 85, 321-329.	0.6	20
110	Plasma levels of tumour necrosis factor- $\alpha$ and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 379-380.	1.4	6
111	Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA A—BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis. <i>Dermatology</i> , 2019, 235, 348-354.	0.9	8
112	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1215-1219.	0.5	29
113	A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 102-110.	0.6	52
114	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 823-828.	0.6	7
115	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019, 15, 153-166.	3.5	208
116	<scp>SEAM</scp>â€œPSA: Seems Like Methotrexate Works in Psoriatic Arthritis?. <i>Arthritis and Rheumatology</i> , 2019, 71, 1027-1029.	2.9	8
117	AB0783â€œ...RELATIVE IMPACT OF JOINT AND SKIN SYMPTOMS ON QUALITY OF LIFE AND WORK PRODUCTIVITY IN PSORIATIC ARTHRITIS (PSA) PATIENTS. , 2019, , .		0
118	AB0742â€œ...ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
119	SAT0390â€œ...GUSELKUMAB WAS MORE EFFECTIVE THAN SECUKINUMAB IN PATIENTS WITH PLAQUE PSORIASIS AND THE SUBSET OF PATIENTS WITH SELF-REPORTED PSORIATIC ARTHRITIS IN THE RANDOMIZED, DOUBLE-BLIND, HEAD-TO-HEAD COMPARISON STUDY ECLIPSE OVER 1 YEAR. , 2019, , .		3
120	AB0738â€œ...DUAL NEUTRALISATION OF INTERLEUKIN (IL)â€œ17A AND ILâ€œ17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY. , 2019, , .		1
121	OP0108â€œ...DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
122	FRI0458â€œ...OBJECTIVE MEASURES OF PSORIASIS SEVERITY AND THE RISK FOR PSA: RESULTS FROM THE INCIDENT HEALTH OUTCOMES AND PSORIASIS EVENTS PROSPECTIVE COHORT STUDY. , 2019, , .		1
123	FRI0452â€œ...TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES. , 2019, , .		0
124	An Approach to Retiform Purpura for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2019, 8, 245-257.	1.1	1
125	TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 70-80.	0.3	67
126	Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey. <i>Rheumatology and Therapy</i> , 2019, 6, 33-45.	1.1	20



#	ARTICLE	IF	CITATIONS
127	Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. <i>Journal of Rheumatology</i> , 2019, 46, 160-165.	1.0	19
128	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus "An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 270-276.	0.3	18
129	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	2.9	312
130	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	1.5	264
131	Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 577-578.	0.6	7
132	Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2019, 129, 1359-1371.	3.9	177
133	Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 28-32.	1.0	2
134	Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. <i>Dermatologic Therapy</i> , 2018, 31, e12589.	0.8	95
135	Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 345-352.	0.6	75
136	A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. <i>British Journal of Dermatology</i> , 2018, 179, 642-650.	1.4	119
137	Inflammatory arthritis and crystal arthropathy: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , 2018, 36, 533-550.	0.8	5
138	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 277-286.e10.	0.6	163
139	Polyarthralgias and Papulonodules in a 56-Year-Old Woman. <i>Arthritis Care and Research</i> , 2018, 70, 925-930.	1.5	0
140	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	0.6	69
141	Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. <i>Journal of Medical Economics</i> , 2018, 21, 745-754.	1.0	10
142	Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation. <i>Clinics in Dermatology</i> , 2018, 36, 551-560.	0.8	15
143	Evaluation of sPGA— BSA as an Outcome Measure and Treatment Target for Clinical Practice. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1955-1961.	0.3	18
144	Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. <i>British Journal of Dermatology</i> , 2018, 178, 1412-1415.	1.4	22

#	ARTICLE	IF	CITATIONS
145	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. <i>British Journal of Dermatology</i> , 2018, 178, 715-721.	1.4	33
146	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
147	THU0313â€¦Ixeikizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors. , 2018, , .		0
148	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. <i>Current Rheumatology Reports</i> , 2018, 20, 76.	2.1	22
149	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119.	0.9	1
150	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. <i>Archives of Dermatological Research</i> , 2018, 310, 701-710.	1.1	10
151	Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study. <i>Rheumatology and Therapy</i> , 2018, 5, 423-436.	1.1	15
152	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 844-852.	1.4	87
153	Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. <i>Clinical Rheumatology</i> , 2018, 37, 2751-2761.	1.0	26
154	Distinguishing rheumatoid arthritis from psoriatic arthritis. <i>RMD Open</i> , 2018, 4, e000656.	1.8	90
155	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165.	0.9	10
156	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137.	2.0	41
157	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , 2018, 154, 934.	2.0	112
158	Targeted therapies for psoriatic arthritis: an update for the dermatologist. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 173-181.	1.6	4
159	AB0929â€¦Burden of skin and joint symptoms of psoriatic disease: results of a multi-national patient survey. , 2018, , .		0
160	GRAPPA 2017 Project Report. <i>Journal of Rheumatology</i> , 2018, 94, 48-51.	1.0	3
161	Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 40-43.	1.0	2
162	Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017, 7, e014733.	0.8	37

#	ARTICLE	IF	CITATIONS
163	Switching biologics in the treatment of psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 29-37.	1.6	69
164	Classifying discoid lupus erythematosus: background, gaps, and difficulties. <i>International Journal of Women's Dermatology</i> , 2017, 3, S62-S66.	1.1	12
165	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. <i>Journal of Rheumatology</i> , 2017, 44, 693-694.	1.0	33
166	Polyphenotypic Psoriasis: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 695-696.	1.0	2
167	Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 691-692.	1.0	2
168	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702.	1.0	9
169	Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 674-678.	1.0	18
170	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	0.6	137
171	Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the Setting of Lupus Panniculitis. <i>JAMA Dermatology</i> , 2017, 153, 944.	2.0	18
172	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 261-267.	0.6	48
173	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (<sc>UNCOVER</sc> 1, <sc>UNCOVER</sc> 2 and <sc>UNCOVER</sc> 3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1686-1692.	1.3	60
174	Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 79-87.e1.	0.6	70
175	SAT0437...Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response. , 2017, , .		0
176	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017, 377, 1537-1550.	13.9	434
177	Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA-BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1178-1180.	0.6	20
178	Novel posterior auricular cutaneous reaction after anti-TNF infusion in young women with Crohn's disease. <i>JAAD Case Reports</i> , 2017, 3, 512-514.	0.4	3
179	OP0216...Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. , 2017, , .		3
180	SAT0222...BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le. , 2017, , .		5

#	ARTICLE	IF	CITATIONS
181	83â€¦Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus. , 2017, , .		1
182	SAT0461â€¦Characterisation of different low disease activity measurements in patients with psoriatic arthritis. , 2017, , .		0
183	405â€¦Temporal relationship of cutaneous lupus erythematosus and systemic lupus erythematosus: a large, retrospective cohort study. , 2017, , .		1
184	Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). BMC Dermatology, 2017, 17, 11.	2.1	8
185	The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and Update. Journal of Drugs in Dermatology, 2017, 16, 119-124.	0.4	12
186	International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group. Journal of Drugs in Dermatology, 2017, 16, 770-777.	0.4	5
187	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. International Journal of Women's Dermatology, 2016, 2, 44-45.	1.1	5
188	Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis. JAMA Dermatology, 2016, 152, 944.	2.0	114
189	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. Journal of Rheumatology, 2016, 43, 959-960.	1.0	8
190	FRI0580â€¦Comorbidity Burden and Medication Use between Psoriatic Arthritis Patients with Moderate-To-Severe Psoriasis vs. Those with Minimal Skin Psoriasis in The US. Annals of the Rheumatic Diseases, 2016, 75, 651.3-652.	0.5	1
191	Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 961-964.	1.0	9
192	Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology. Journal of Investigative Dermatology, 2016, 136, 1325-1329.	0.3	5
193	Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature. Dermatology, 2016, 232, 97-101.	0.9	27
194	Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects. American Journal of Clinical Dermatology, 2016, 17, 147-162.	3.3	20
195	Classifying discoid lupus erythematosus: background, gaps, and difficulties. International Journal of Women's Dermatology, 2016, 2, 8-12.	1.1	7
196	Epidemiology and Treatment of Eosinophilic Fasciitis. JAMA Dermatology, 2016, 152, 97.	2.0	60
197	Histopathology of the Inner Ear in a Case With Recent Onset of Coganâ€™s Syndrome. Annals of Otology, Rhinology and Laryngology, 2016, 125, 20-24.	0.6	27
198	Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire. Journal of Drugs in Dermatology, 2016, 15, 1011-6.	0.4	10

#	ARTICLE	IF	CITATIONS
199	Mosaic focal dermal hypoplasia caused by a novel somatic mutation in <i>PORCN</i> detected in affected skin. <i>British Journal of Dermatology</i> , 2015, 173, 568-570.	1.4	9
200	Treatment of coexistent psoriasis and lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 253-260.	0.6	36
201	The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 345-348.	0.6	44
202	Psoriatic arthritis: It's as easy as PSA. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 905-906.	0.6	13
203	Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing. <i>Journal of Rheumatology</i> , 2015, 42, 847-852.	1.0	19
204	Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 701-702.	0.6	23
205	Psoriasis, psoriatic arthritis and risk of gout in US men and women. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1495-1500.	0.5	67
206	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	1.0	18
207	Psoriatic arthritis screening tools: study design and methodological challenges. <i>British Journal of Dermatology</i> , 2014, 170, 994-995.	1.4	2
208	Diagnosing and treating psoriatic arthritis: an update. <i>British Journal of Dermatology</i> , 2014, 170, 772-786.	1.4	28
209	Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. <i>Lupus</i> , 2014, 23, 778-784.	0.8	50
210	The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): A Novel Index to Measure All Non-plaque Psoriasis Subsets. <i>Journal of Rheumatology</i> , 2014, 41, 1230-1232.	1.0	12
211	Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 19-24.	0.6	36
212	Is chronic cutaneous discoid lupus protective against severe renal disease in patients with systemic lupus erythematosus?. <i>Journal of Drugs in Dermatology</i> , 2011, 10, 1413-20.	0.4	13